Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Mengqiu Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project, National Natural Science Foundation of China, Postdoctoral Science Foundation of China.
Abstract (Originalsprache)
The worldwide incidence and mortality rates of esophageal squamous cell carcinoma (ESCC) have increased over the last decade. Moreover, molecular targets that may benefit the therapeutics of patients with ESCC have not been fully characterized. Our study discovered that thousand and one amino‐acid protein kinase 1 (TAOK1) is highly expressed in ESCC tumor tissues and cell lines. Knock‐down of TAOK1 suppresses ESCC cell proliferation in vitro and patient‐derived xenograft or cell‐derived xenograft tumors growth in vivo. Moreover, TAOK1 overexpression promotes ESCC growth in vitro and in vivo. Additionally, we identified that the natural small molecular compound resveratrol binds to TAOK1 directly and diminishes the kinase activity of TAOK1. Targeting TAOK1 directly with resveratrol significantly inhibits cell proliferation, induces cell cycle arrest and apoptosis, and suppresses tumor growth in ESCC. Furthermore, the silencing of TAOK1 or the application of resveratrol attenuated the activation of TAOK1 downstream signaling effectors. Interestingly, combining resveratrol with paclitaxel, cisplatin, or 5‐fluorouracil synergistically enhanced their therapeutic effects against ESCC. In conclusion, this work illustrates the underlying oncogenic function of TAOK1 and provides a theoretical basis for the application of targeting TAOK1 therapy to the clinical treatment of ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, School of Basic Medical Sciences, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China.
- China-US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China.
- State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou, Henan, China.
- The Academy of Medical Science, College of Medicine, Zhengzhou University, Zhengzhou, Henan, China.
- Department of Pharmaceutical Science & Engineering, Seowon University, Cheongju, South Korea.
- The Hormel Institute, University of Minnesota, Austin, Minnesota, USA.
Förderung
- Henan Provincial Science and Technology Research Project
- National Natural Science Foundation of China
- Postdoctoral Science Foundation of China
Zitieren
APA
Song, M., Qu, Y., Jia, H., Zhang, Y., Liu, S., Laster, K. V., Choi, B. Y., Tian, J., Gu, T., Chen, H., Liu, K., Lee, M. H., & Dong, Z. (2024). Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23703
Vancouver
Song M, Qu Y, Jia H, Zhang Y, Liu S, Laster KV, et al. Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23703
BibTeX
@article{Song2024,
author = {Song, Mengqiu and Qu, Yingzi and Jia, Huajie and Zhang, Yunqing and Liu, Shihui and Laster, Kyle Vaughn and Choi, Bu Young and Tian, Jie and Gu, Tingxuan and Chen, Hanyong and Liu, Kangdong and Lee, Mee-Hyun and Dong, Zigang},
title = {Targeting TAOK1 with resveratrol inhibits esophageal squamous cell carcinoma growth in vitro and in vivo},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23703}
}
EUVIMED